Robert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Dianthus Therapeutics (NASDAQ:DNTH - Free Report) had its price target trimmed by Robert W. Baird from $58.00 to $50.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other equities analysts have also recently commented on DNTH. Guggenheim reaffirmed a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Finally, Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $53.00.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock traded up $0.94 during midday trading on Tuesday, reaching $19.69. 338,777 shares of the company's stock were exchanged, compared to its average volume of 271,018. The stock's 50-day simple moving average is $19.40 and its 200 day simple moving average is $22.11. The firm has a market cap of $633.23 million, a price-to-earnings ratio of -7.88 and a beta of 1.48. Dianthus Therapeutics has a 52 week low of $13.37 and a 52 week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.04. The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.81 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. R Squared Ltd bought a new position in shares of Dianthus Therapeutics during the fourth quarter worth approximately $26,000. KLP Kapitalforvaltning AS acquired a new stake in Dianthus Therapeutics during the fourth quarter worth approximately $33,000. US Bancorp DE increased its stake in Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after acquiring an additional 1,510 shares during the period. KBC Group NV acquired a new position in Dianthus Therapeutics in the 4th quarter valued at $35,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth $59,000. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.